Wy 49051
CAS No. 113418-56-7
Wy 49051 ( Wy-49051 )
产品货号. M26508 CAS No. 113418-56-7
Wy 49051 is an orally active antagonist of H1 receptor(IC50 of 44 nM).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥4026 | 有现货 |
|
10MG | ¥5856 | 有现货 |
|
25MG | ¥9153 | 有现货 |
|
50MG | ¥12312 | 有现货 |
|
100MG | ¥16038 | 有现货 |
|
500MG | ¥32157 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Wy 49051
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Wy 49051 is an orally active antagonist of H1 receptor(IC50 of 44 nM).
-
产品描述Wy 49051 is an orally active antagonist of H1 receptor(IC50 of 44 nM).(In Vitro):Wy 49051 showed a great inhibitory effect on H1. At a concentration of 100 nM, it produced 92% inhibition of histamine-induced guinea pig ileal contraction. Wy 49051 is the most effective compound, with 700 times the potency of astemizole and 470 times the potency of hydroquinone. Wy 49051 also has high affinity for α1 receptor with IC50 of 8 nM.(In Vivo):Wy 49051 shows against histamine-induced lethality in the guinea pig(ED50 of 1.91 mg/kg by po, 0.70 mg/kg by ip, and 0.01 mg/kg by iv). The duration of action of 24 is also favorable since there is no decrease in oral efficacy up to 18 h posttreatment.
-
同义词Wy-49051
-
通路Angiogenesis
-
靶点ALK
-
受体Arenavirus
-
研究领域——
-
适应症——
化学信息
-
CAS Number113418-56-7
-
分子量487.6
-
分子式C28H33N5O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCn1c2ncn(CCCN3CCC(CC3)OC(c3ccccc3)c3ccccc3)c2c(=O)n(C)c1=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Carney DW, et al. Structural optimization of a retrograde trafficking inhibitor that protects cells from infections by human polyoma- and papillomaviruses. Bioorg Med Chem. 2014 Sep 1;22(17):4836-47.
产品手册
关联产品
-
GSK1838705A
GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
-
CPI-169
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
-
LDN212854
LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors.